Related Experiment Videos
Cardiac allograft vasculopathy: a review
1Medizinische Klinik und Poliklinik I, Klinikum Grosshadern, University of Munich, Germany. Micha.Weis@t-online.de
Insights
Cardiac allograft vasculopathy (CAV) is an accelerated coronary disease after heart transplants, driven by immune responses and risk factors. Current treatments aim to manage immune response and slow disease progression.
Area of Science:
- Cardiology
- Immunology
- Transplantation Medicine
Background:
- Cardiac allograft vasculopathy (CAV) is a significant long-term complication following heart transplantation.
- It presents as an accelerated form of coronary artery disease affecting both intramural and epicardial vessels.
- CAV pathogenesis involves immune response, ischemia-reperfusion, infections, immunosuppressants, and traditional risk factors.
Purpose of the Study:
- To review the pathogenesis, morphology, and management strategies for cardiac allograft vasculopathy.
- To elucidate the complex factors contributing to the development and progression of CAV.
- To discuss current and potential therapeutic interventions for CAV.
Main Methods:
- Review of existing literature on cardiac allograft vasculopathy.
- Analysis of pathogenetic mechanisms including immune response, endothelial injury, and repair.
- Examination of diagnostic findings from intracoronary ultrasound studies.
- Evaluation of current and emerging treatment strategies.
Main Results:
- CAV is characterized by unique vascular injury and accelerated coronary disease.
- Pathogenesis involves multiple stimuli leading to repetitive endothelial injury and repair.
- Intracoronary ultrasound shows dual morphology: focal proximal plaques and diffuse distal concentric patterns.
- Apoptosis and impaired vascular remodeling are key mediators.
- Discordant progression between microvascular and epicardial disease is observed.
Conclusions:
- Effective management of CAV requires addressing immune responses and traditional cardiovascular risk factors.
- Strategies targeting T-cell costimulation and adhesion molecules show promise.
- Statins and antiproliferative drugs may slow CAV progression.
- Augmenting nitric oxide bioavailability and novel immunosuppression may be protective.
- Interventional and surgical options have limited efficacy, and retransplantation outcomes are poor.
Abstract:
Cardiac allograft vasculopathy (CAV) remains a troublesome long-term complication of heart transplantation. It is manifested by a unique and unusually accelerated form of coronary disease affecting both intramural and epicardial coronary arteries and veins.CAV is characterized by vascular injury induced by a variety of noxious stimuli, including the immune system response to the allograft, ischemia-reperfusion injury, viral infection, immunosuppressive drugs, and classic risk factors such as hyperlipidemia, insulin resistance, and hypertension. The obstructive vascular lesions are thought to progress through repetitive endothelial injury followed by repair response. The role of major histocompatibility complex donor-recipient differences in the pathogenesis of CAV has not yet been completely elucidated. Intracoronary ultrasound studies reveal a dual morphology with donor-transmitted or de novo focal, noncircumferential plaques in proximal segments and/or a diffuse, concentric pattern observed in distal segments. A lack of correlation between microvascular and epicardial vessel disease suggests discordant manifestations and progression of CAV. Apoptosis and loss of functional vascular remodeling have to be considered as important mediators of clinically relevant CAV. Strategies for blocking T-cell costimulation and expression of adhesion molecules may help prevent chronic rejection in clinical transplantation. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and antiproliferative drugs may slow progression of CAV by various effects. Methods to augment endogenous nitric oxide bioavailability as well as newer immunosuppressive regimens may be protective. Balloon angioplasty has a limited role in the treatment of focal lesions. Experiences with coronary stenting, coronary artery bypass grafting, and transmyocardial laser revascularization are limited. Retransplantation has a worse outcome than initial transplantation.